Realistically you are looking at five years before any approval. The chance of success is <8% (on average).
The median phase III trial in their data set cost $21.4 million, they reported last year in Nature Reviews Drug Discovery. The median phase II trial cost $8.6 million, and the median phase I trial cost $3.4 million, they also reported.
https://www.nature.com/articles/nrd.2018.198
From the FDAStep 3: Clinical Research
Phase 2
Study Participants:Up to several hundred people with the disease/condition.
Length of Study: Several months to 2 years
Approximately 33% of drugs move to the next phase
Phase 3
Study Participants:300 to 3,000 volunteers who have the disease or condition
Length of Study: 1 to 4 years
Approximately 25-30% of drugs move to the next phase
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- Forums
- ASX - By Stock
- CUV
- Ann: Media release - First stroke patient with afamelanotide
Ann: Media release - First stroke patient with afamelanotide, page-11
-
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.12 |
Change
0.250(1.80%) |
Mkt cap ! $706.8M |
Open | High | Low | Value | Volume |
$13.90 | $14.17 | $13.90 | $675.2K | 48.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 293 | $14.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.12 | 261 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 900 | 14.000 |
1 | 729 | 13.950 |
1 | 2000 | 13.910 |
2 | 539 | 13.860 |
1 | 600 | 13.850 |
Price($) | Vol. | No. |
---|---|---|
14.250 | 500 | 1 |
14.280 | 833 | 1 |
14.430 | 668 | 1 |
14.460 | 709 | 1 |
14.560 | 5000 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |